These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37603328)

  • 21. Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.
    Metz LM; Li DKB; Traboulsee AL; Duquette P; Eliasziw M; Cerchiaro G; Greenfield J; Riddehough A; Yeung M; Kremenchutzky M; Vorobeychik G; Freedman MS; Bhan V; Blevins G; Marriott JJ; Grand'Maison F; Lee L; Thibault M; Hill MD; Yong VW;
    N Engl J Med; 2017 Jun; 376(22):2122-2133. PubMed ID: 28564557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
    Miller AE
    Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
    Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
    Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome.
    Lebrun-Frénay C; Rollot F; Mondot L; Zephir H; Louapre C; Le Page E; Durand-Dubief F; Labauge P; Bensa C; Thouvenot E; Laplaud D; de Seze J; Ciron J; Bourre B; Cabre P; Casez O; Ruet A; Mathey G; Berger E; Moreau T; Al Khedr A; Derache N; Clavelou P; Guennoc AM; Créange A; Neau JP; Tourbah A; Camdessanché JP; Maarouf A; Callier C; Vermersch P; Kantarci O; Siva A; Azevedo C; Makhani N; Cohen M; Pelletier D; Okuda D; Vukusic S;
    JAMA Netw Open; 2021 Oct; 4(10):e2128271. PubMed ID: 34633424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.
    Jiang T; Ziemssen T; Wray S; Shen C; Söderbärg K; Lewin JB; Božin I; Freedman MS
    CNS Drugs; 2023 May; 37(5):441-452. PubMed ID: 37155132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.
    Miller AE; Xu X; Macdonell R; Vucic S; Truffinet P; Benamor M; Thangavelu K; Freedman MS
    J Clin Neurosci; 2019 Jan; 59():229-231. PubMed ID: 30348586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
    Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
    Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome.
    Longbrake EE; Hua LH; Mowry EM; Gauthier SA; Alvarez E; Cross AH; Pei J; Priest J; Raposo C; Hafler DA; Winger RC
    Mult Scler Relat Disord; 2022 Dec; 68():104143. PubMed ID: 36031693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
    Chan A; de Seze J; Comabella M
    CNS Drugs; 2016 Jan; 30(1):41-51. PubMed ID: 26758290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiologically isolated syndrome: A single-center, retrospective cohort study.
    George IC; Rice DR; Chibnik LB; Mateen FJ
    Mult Scler Relat Disord; 2021 Oct; 55():103183. PubMed ID: 34365315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
    Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
    BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
    Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
    Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.
    Vieira MC; Conway D; Cox GM; Peeples M; Bensimon AG; Macheca M; Herrera V
    Curr Med Res Opin; 2020 Feb; 36(2):261-270. PubMed ID: 31694401
    [No Abstract]   [Full Text] [Related]  

  • 37. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
    Sprenger T; Kappos L; Sormani MP; Miller AE; Poole EM; Cavalier S; Wuerfel J
    Mult Scler; 2022 Oct; 28(11):1719-1728. PubMed ID: 35485424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab for multiple sclerosis.
    Riera R; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.